XORTX Therapeutics (TSXV:XRTX) GF Score: 30/100 (As of Aug. 02, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:XRTX XORTX Therapeutics Inc TSXV:XRTX
30 GF Score
Price C$2.84
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics GF Score?

XORTX Therapeutics TSXV:XRTX 30 GF Score is 30 as of Aug. 02, 2026, which is 6% below its 10-year median of 32.00. GuruFocus rates TSXV:XRTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

XORTX Therapeutics has the GF Score of 30, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes XORTX Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

XORTX Therapeutics  (TSXV:XRTX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

XORTX Therapeutics GF Score Related Terms

TSXV:XRTX vs VRTX, REGN, RVMD: GF Score Comparison

For the Biotechnology subindustry, XORTX Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's GF Score falls into.


TSXV:XRTX
30GF Score
XORTX Therapeutics Inc TSXV:XRTX
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 30 mean?
XORTX Therapeutics (TSXV:XRTX) has a GF Score of 30 as of Aug. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XORTX Therapeutics and its competitors. This is near median its historical median of 32.00. Over the past decade, XORTX Therapeutics' GF Score has ranged from 4.00 to 42.00.
Is XORTX Therapeutics' GF Score too high?
XORTX Therapeutics' current GF Score of 30 is near median its 10-year median of 32.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 42.00. Overall, XORTX Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' GF Score compare to VRTX and REGN?
XORTX Therapeutics' GF Score of 30 can be compared against companies in the Biotechnology industry. Historically, XORTX Therapeutics' own GF Score has ranged from 4.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XORTX Therapeutics and its competitors. XORTX Therapeutics's current GF Score is 30, which is near median its own 10-year median of 32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (TSXV:XRTX) has a current GF Score of 30. The current GF Score is 30, which is near median its 10-year median of 32.00. XORTX Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For XORTX Therapeutics (TSXV:XRTX), the current GF Score is 30 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XORTX Therapeutics Business Description

Other Exchanges XRTX:USAANU:Germany
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
30GF Score

Get the complete analysis for TSXV:XRTX

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.84
Price